# MA 2027 Funding Halved and Medicare Launches a GLP-1 Bridge Program - Managed Care Under Pressure - Week of June 27, 2026 > Managed-care podcast briefing for the week of June 20-27, 2026. An MA distribution operator quantified the 2027 funding squeeze (carriers got 'less than half' of last year's +5.06%, average MA MLR 'over 90%'), Medicare's GLP-1 Bridge Program goes live July 1 with the federal government absorbing the cost, and IQVIA reframed GLP-1s as only about one point of total drug-spend growth. ## Managed Care Under Pressure ### Week of June 27, 2026: MA 2027 Funding Halved and Medicare Launches a GLP-1 Bridge Program --- ## TL;DR - **Most actionable item:** an MA distribution operator quantified the 2027 funding squeeze from the field. Carriers got "**less than half**" of last year's +5.06%, average MA medical loss ratio is "**over 90%**," and AEP 2027 is being called a "**blood fest**" of plan exits and benefit cuts. A direct read on UNH/HUM/CVS/CI MA margins. - **New GLP-1 wrinkle for Medicare:** CMS launches the **Medicare GLP-1 Bridge Program on July 1, 2026**, paying for weight-loss GLP-1s *outside* Part D, so the government, not the Part D/MA plans, absorbs that cost, with a hard cliff at end-2027. Separately, IQVIA data reframed GLP-1s as only about one point of total drug-spend growth. - **The DOJ overhang did not move.** UnitedHealth went on the record repositioning as a technology and data company, but with no MLR figure, no guidance reinstatement, and no DOJ update. --- ## What's new **1. The 2027 MA funding cut, quantified from the distribution trenches.** On [The Seven Figures Or Bust Podcast! - "Episode 242: CMS, Carriers & Chaos … What's Next?" (2026-06-26)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhwra0Zgj-2FJMwRmiwvRT3sZl1efPs6OFBu3eRwOZoojxw6q-2BQ-2B6-2FaiymYI6hqzICBo4tBB001anM49Km-2BlKnig9npT4s-2F0pdnhKv821A9ojuA-3D-3DQs51_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3quXpSoHgSsfnbBCaGAPQbH7ATGfDWPSdG-2BoYKSlrUwK9SyHhc5I5976GqlWalYH76ZvsFOoJKkKSc9pAXxfGwjQ1tcZPBmEVNaO1kn9EigT3QjvsiMaJJehriHerlkmfQ-3D-3D), MA field operator Andrew Saul (insurance distribution, not a company exec) laid out the math: last year carriers got a +5.06% rate, "and this year they got left less than half of that in funding." He pegged the proposed rate at roughly a flat "0.09%... up to 2.48[%]" and said "the average MLR in a Medicare Advantage plan is over 90% right now across the nation," with plans that "operate on a 1% profit margin... now 4% over where their profit margin was." His call: "AEP 27 is going to be more of a blood fest... the year of the HMO and the D-SNP and C-SNP," with regional PPOs going non-commissionable and benefit cuts deepening. **Why it matters:** field-level confirmation that the 2027 MA rate (about +2.5%, less than half of 2026's 5.06%) is below trend, and that carriers are responding with the exact margin-defense playbook (PPO exits, benefit cuts, prior-auth tightening) that drives 2027 EPS for UNH, HUM, CVS/Aetna and CI. **2. UnitedHealth on the record, repositioning as "the Apple of healthcare."** On [Becker's Healthcare Podcast - "Inside UnitedHealth Group's AI and Technology Strategy" (2026-06-23)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjQaCDgv8WDHOV-2BypwbQxfEHu8ADqiVh7lWJJ4dva7Se9MVeRRycmjQn4z8ZCqtdRlFWQzLh7-2B7M70THRTAKVvqg846Rn0cYAYs2TFNb8KXrg-3D-3D51LM_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3iybkk8b-2Fc6JtLeK2blsvS3jYnMpK71FOT-2FANlCG1kL1K6tQkEY5qRbDTCAJ9I89JazXrdzysFHYkhvhfqYB31zltD3rGYjp70j8USeFLejbA-2F1tHQSzNqj5NN2inIAIgQ-3D-3D), payer journalist Jakob Emerson relayed on-the-record commentary from a UNH HQ visit with senior executives including the CEOs of UnitedHealthcare and Optum. UnitedHealthcare COO Mike Baker, on the 2024 CEO murder and the backlash: "you paused, a soul search a little bit. And you ask yourself, am I missing something here? Are we really part of the problem and not part of the answer?" Emerson's takeaway: UNH is presenting as "a technology and data company," investing "$3 billion total between this year and next year combined" in AI, with "a thousand AI use cases currently in production," monetizing claims-coding and scheduling software through Optum Insight. **Why it matters (operator commentary):** narrative management, not numbers. No MLR figure, no guidance reinstatement, and crucially **no DOJ update**. The DOJ-overhang thread from prior weeks did not advance. **3. Mark Cuban turns the PBM/MLR bear case into a soundbite.** On [CareTalk - "Why Healthcare Prices Are Like Fight Club w/ Mark Cuban" (2026-06-26)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhnOw6Ci0pcy2AvoZmpeHnQr-2FZ-2FSZfBYoKlAfGUxq9jIFGOfYbyaEODXv3HnY0WvfAP3X4U0uGQwslS1qmSfHef7mrgiSk2KuCnq7G4wQLb7Q-3D-3DGL1K_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3hVSxkLCAh69U-2FXlC8tWVd7w-2FhrxHaqqZgEwXWTdiMl79pwFdsnhC3s-2BwlFEEyUpBpwj6U-2FGTeujk58a47kZHWZTmlz-2FU59dyBSVfPSS2XI0txU0OJF93liyzsq3ya1bJQ-3D-3D), the Cost Plus Drugs founder (industry entrepreneur and pundit) argued the big PBMs "control the formularies for 85% of insured people," use formulary-demotion threats to keep brand net prices about 50% of list, and, most relevant to insurers, that vertically integrated conglomerates "game the ACAs by owning providers... and they charge themselves more so that they can game the medical loss ratios," citing "$160 billion in annual intercompany transfers." On reform: state-level fixes on reimbursement and self-steering are "happening in multiple states," but the federal Hawley-Warren "breakup big medicine bill" is "pretty much dead in the water." **Why it matters (pundit, not operator):** sharpens the multi-year-political-overhang bear case on UNH/Optum Rx, CVS/Caremark and CI/Express Scripts, while signaling the most dangerous federal break-up risk is, for now, stalled. **4. Medicare GLP-1 Bridge Program goes live July 1, government eats the cost.** On [NEJM Interviews - "Stacie Dusetzina on the Medicare GLP-1 program" (2026-06-24)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjk9XmTMNu2o7EDblubrzURPcMUUbdvR5Kk4Svq9Ee0o9CoBl-2BZi-2BVb1Eu-2B2ciZtetIDUoHwnMAWjJbVAfDshHQ-2BNX8j0Vdis25NssN2cD2hQ-3D-3D-UfC_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3n5JHnwb9hqOyv8muK4Mrp30n37QNZeMPWcWcAT89hUSQl-2B0CoRbmm-2BFKbBDKhqeRGD3c-2BdDVdzd2UVYgm-2BFHC-2BoxrrIaEiSXvWpSejALUa-2BotO-2BLSNZTbsaB6heFhw7NA-3D-3D), the Vanderbilt health-policy economist explained CMS will cover weight-loss GLP-1s "completely outside of the Medicare Part D benefit" starting July 1, 2026, "the government is paying for these drugs separate from the program." The broader Balance demonstration is on hold (Part D plan sponsors declined the voluntary model); Bridge now runs only through end-2027, with no successor and an "unclear" off-ramp. **Why it matters:** because the cost sits with the federal government, not the plans, this is a modest relief on the GLP-1-cost-explosion fear for MA/Part D sponsors on the weight-loss indication they weren't covering anyway, but it creates a 2027 cliff and could pressure Part B premiums. **5. Drug spend is up double digits, but GLP-1s are only about one point of it.** On [The Astonishing Healthcare Podcast - "AH110: Inside the 2026 U.S. Medicine Use Trends Report" (2026-06-26)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhsMYcaFtWA6fhUjih0IcwGKx40ep334UPLiHJapb9hxc3Rgwsbis21bTr1bxWlWOEBjSh9DXN-2FtOiGFrc-2F-2BazZet58FCO4zgt0x-2BBa50POlQ-3D-3DvzJT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3vg8EltZNtygNu9amfD6XbIU98M5RzZvvIgk3LIACGyNFYMtGbnGZ2jipoSfT3NsfcZ42xPt-2F45KrITU3cGlEKGwFzirhLhhZyS7HbNgs89BjwGNVUPh2KQCVpiT-2B5PPcQ-3D-3D), IQVIA's Michael Kleinrock reported US medicine spend hit "$606 billion in 2025... up 10.6%" (after +14.4% in 2024), but "only... a percentage point of the current growth" came from GLP-1s. The other 9.6 points are spread across dozens of mid-life oncology, immunology and neurology products. He flagged the about $670B gross-to-net spread ($1.363T list vs $606B net) and warned that IRA price negotiation, by stripping rebates, removes the cross-subsidy "that keeps premiums from rising." **Why it matters:** partially de-escalates the GLP-1-will-break-payers narrative, but confirms the underlying specialty-drug trend that keeps pressuring MLRs is broad and double-digit, not a GLP-1 one-off. ## The debate **Bull (margins have bottomed, 2027 is the repricing year):** The 2027 rate at about +2.5% is below trend, but carriers know it, and the field tape confirms they are repricing hard into AEP 2027 (PPO exits, benefit cuts, prior-auth tightening, a pivot to HMOs/D-SNPs/C-SNPs where risk dollars are richest). The Medicare GLP-1 Bridge moves weight-loss cost onto the federal balance sheet, and IQVIA's data says GLP-1s are only about one point of drug-trend growth. The federal PBM/insurer break-up bill is dead in the water. Discipline plus a known-bad rate equals margin recovery into 2027. **Bear (a structural, multi-year reset):** Average MA MLR "over 90%" is not a one-quarter blip; carriers running about 1% margins are now four points underwater. The funding cut is real and below trend, utilization isn't trending down ("not a single thing is trending down"), and the specialty-drug curve is broadly double-digit. Layer on the political overhang (MLR-gaming accusations aimed squarely at vertically integrated names, plus the unresolved DOJ thread at UNH) and you get multiple compression, not just an earnings air-pocket. ## Stocks in play - **UNH** - *Bull:* on-record repositioning as a tech/data platform, $3B AI build, Optum Insight software monetization; about +2.5% 2027 rate is a known headwind to reprice against. *Bear:* avg MA MLR >90% pressures the core; the Cuban-style MLR-gaming/PBM political narrative targets Optum Rx; the DOJ coding probe did **not** advance this week and remains an unquantified overhang. *Catalyst:* Q2'26 print (MLR vs guide, any FY26 EPS reinstatement), DOJ procedural movement, 2027 bid color. - **CVS** - *Bull:* Aetna leverage to the 2027 reprice; Caremark scale. *Bear:* Caremark sits inside the federal/state PBM-transparency frame and the MLR-gaming critique; GLP-1 cost optics. *Catalyst:* Q2'26 Aetna MLR, Caremark GLP-1 economics, any strategic-review update. - **HUM** - *Bull:* cleanest pure-play MA leverage to a known-bad 2027 rate; benefits most if discipline holds. *Bear:* highest beta to the >90% MA MLR backdrop and any further rate/benefit erosion. *Catalyst:* Q2'26 MLR, 2027 bid/benefit-design color. - **CI** - *Bull:* Evernorth growth; MA exit removed funding-cycle drag. *Bear:* Express Scripts squarely in the PBM-reform and MLR-gaming frame. *Catalyst:* Q2'26 Evernorth growth, PBM rulemaking calendar. - **ELV** - *Bull:* Carelon offset; MA reprice. *Bear:* Medicaid work-requirement attrition plus ACA subsidy cliff souring the risk pool. *Catalyst:* Q2'26 Medicaid/MA MLR splits. - **CNC** - *Bull:* exchange margins, maturing Medicaid acuity reset. *Bear:* most exposed to the ACA enhanced-subsidy cliff and procedural Medicaid disenrollment. *Catalyst:* Q2'26 HBR by segment. - **MOH** - *Bull:* disciplined Medicaid underwriting. *Bear:* most Medicaid-levered to work requirements plus state-directed-payment caps. *Catalyst:* Q2'26 MCR, RFP wins/losses. ## Read-throughs - **Medicaid / exchange insurers (CNC, MOH, ELV):** the coverage-loss thread stayed hot. On [Health & Veritas (2026-06-25)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiZYEqriOCJR3AoiLFFSkuq-2FK9TWAu3E-2BaWGUjK5NIa-2BmAfhlEm86plH9HaKpOxw-2Fa8Qa-2FBqIfBAl4-2BjBpkRq087Gx09q-2FVEkix7mXrchpkkA-3D-3Dxf8n_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3p2ujrocevu99a3qE6cPSTAe-2BC1muV8sgVLaM-2FjUXJGOVWm1LyWpXwYeYLgmmbmK0VyuJXd-2BevD3j4mP10LEf7talcRX6slnAjf9l0hT5vsRcEUisMvWvUfpo0rvQzgFJw-3D-3D), the hosts noted a new federal rule tightening Medicaid work-requirement medical exemptions, with states to comply by January 2027, citing Arkansas's 2018 experiment where "18,000 people lost coverage in four months" despite 95% already qualifying. On [Tradeoffs (2026-06-25)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjiCO6xNOLOejROP7-2BX4PP35oY5592chfZrXSUEIyEYCj3Aqa0-2BrUY3wqbr2G9Ov8nbH9rxi6z7vZ0P2uvoKRVQqp46THw-2BKt4qWXNGIVsCFA-3D-3DmCEj_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3qExU9A0fEuom-2Ft28syudN8DzzacMqqwnSk6w8-2BsKs0pj-2BRA4po2GiVlKwpuPbX8infQrvm49Pfl6y1hu0QzLlxqfjvfyjhvl6HnG9QFc66n6292kZvlpGyuIRuanFhG6g-3D-3D), Stanford's Neale Mahoney sized the ACA cliff: "5.8 million people could drop Obamacare plans" as enhanced subsidies lapse. Read-through: deteriorating acuity mix and membership attrition into 2027 for the Medicaid/exchange-heavy names. - **PBMs / Optum-style arms:** the Cuban critique plus [Relentless Health Value EP517 (2026-06-24)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiqbSbm4nPTdi4ZZY-2BCWQziAXzRM-2Fyootu5wvWkZaYH46JXbOBaDm15pXIHnAlFSf2IWVVrd1Hq-2F-2BoWK4OSBAGh32Jjo5gAzOw8VW-2BEDq6B-2Bg-3D-3DGObv_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3lSkT0IfscMBHSMD35WCSom3uPLpGmobDezn2-2BZDi0tjfmhAmwHblcPhURcHH-2BGXQeX-2FuDLRmjoda02MzEwhH-2FDyzJvaghprP0zs1mILl6B5RrFPEeoqxt0fj3ZbaXFahQ-3D-3D) (where Stacey Richter argued PBMs place drugs behind prior-auth to maximize rebates, not for clinical reasons) and [The Liquid Lunch Project (2026-06-24)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjvITfS5364s7D51njqZzXHQEQt4uTZdE22W-2F2F66ybhPIeTUblXm1MSDcMvjzs9oUZmo7KzXer12eyoBpXFGwe-2BVDaw5sNeT55i098q62XUQ-3D-3DobhV_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3ifZsWsizMRSwf4gwyHQXeEC38sjGd-2FS6RruF-2FqQSiF0r-2BANvXCfh0BaQdG1CW3BMxLGkeXv0g2bZDLYojTZ-2F7wGr70XwCXVvzj3p8-2BHHKL9UxO-2BBXoYO-2F-2Fdu65ehC1Kpw-3D-3D) keep the PBM-transparency narrative alive. Federal break-up risk stalled; state-level reimbursement/steering rules advancing. - **Providers / hospitals (other side of utilization):** [Achieving Health - "Washington Watch" (2026-06-24)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi56PLI2i3MUuHMjkQMOiA3n7VkQFovURYCrUmmFDdUuri5P41Hys3kfPHbMVAFJhs72WS3pOfzSiO-2B6gXxjLZ8p239pAZ-2FgtYWWJB44g5cyA-3D-3Dzgw2_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX3lfMVZI1s0Wf4V04GrLy5acYsknWZ-2BlYMgt-2F-2BxMJW3lbf8kucqgiveA9ytAUHSKA5spUDtpdJD9FgG08JXA923n3wZ46ESvgP5SwOWmOrzTY8f-2FJl9UTDeUCalnZuuteO0NPQWaVCqoZJqrpTrvLsV2TAcebDRhkjy8R6GJYpRg-3D-3D) flagged work requirements and more-frequent eligibility checks beginning January 1, 2027, plus provider-tax/SDP changes, the cost-shift mechanism that lands on commercial rates. - **GLP-1 cost exposure:** the Medicare Bridge (July 1) moves weight-loss GLP-1 cost to the federal government; IQVIA frames GLP-1s as only about one point of drug-trend growth. Net: the GLP-1-as-payer-catastrophe story softened modestly this week, even as the broad specialty-drug curve stays double-digit. ## What changed vs last week - **MA 2027 rate, confirmed and quantified from the field.** Last week we were still waiting on follow-on commentary to the about +2.5% final rate. This week the distribution channel put numbers on it ("less than half" of 5.06%, avg MA MLR ">90%", AEP 27 "blood fest"), directional confirmation, now with operational consequences attached. - **GLP-1 angle moved from PBM formulary to Medicare.** Last week's story was CVS Caremark reversing its Zepbound exclusion under ERISA pressure. This week the lens shifted to Medicare's Bridge Program (government-funded, July 1) and IQVIA's "only about one point of growth" reframe, a partial de-escalation of payer GLP-1 fear. - **UNH, operator color, but the DOJ thread did NOT advance.** Last week was an AI-pundit "binary/DOJ" reframe. This week we got genuine on-record operator commentary (COO Mike Baker, $3B AI, Optum Insight), but no DOJ movement, no guidance, no MLR. The overhang is unchanged.